首页> 美国卫生研究院文献>Journal of Neurological Surgery. Part B Skull Base >Gamma Knife Stereotactic Radiosurgery for Grade 2 Meningiomas
【2h】

Gamma Knife Stereotactic Radiosurgery for Grade 2 Meningiomas

机译:伽玛刀立体定向放射外科治疗2级脑膜瘤

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Purpose  This study aims to report long-term clinical outcomes after Gamma Knife radiosurgery (GKRS) for intracranial grade 2 meningiomas. >Methods  In this Institutional Review Board approved study, we reviewed records of all patients with grade 2 meningiomas treated with GKRS between 1998 and 2014. >Results  A total of 97 postoperative histopathologically confirmed grade 2 meningiomas in 75 patients were treated and are included in this study. After a mean follow-up of 41 months, 28 meningiomas had local recurrence (29.79%). Median time to local recurrence was 89 months (mean: 69, range: 47–168). The 3- and 5-year actuarial local control (LC) rates were 68.9 and 55.7%, respectively. The 3- and 5-year overall survival rates were 88.6 and 81.1%, respectively. There was a trend toward worse LC with tumors treated with radiation doses ≤ 13 versus > 13 Gy. There was no radiation necrosis or second malignant tumors noted in our series. >Conclusion  This report, one of the largest GKRS series for grade 2 meningiomas, demonstrates that GKRS is a safe and effective treatment modality for patients with grade 2 meningiomas with durable tumor control and minimal toxicity. Adjuvant GKRS could be considered as a reasonable treatment approach for patients with grade 2 meningiomas.
机译:>目的这项研究旨在报告颅内2级脑膜瘤的伽玛刀放射手术(GKRS)后的长期临床结果。 >方法在该机构审查委员会批准的研究中,我们回顾了1998年至2014年期间所有接受GKRS治疗的2级脑膜瘤患者的记录。>结果总共进行了97例经病理组织学确认的术后本研究纳入了75例患者中的2例脑膜瘤。平均随访41个月后,有28例脑膜瘤发生局部复发(29.79%)。局部复发的中位时间为89个月(平均:69,范围:47-168)。 3年和5年精算本地控制(LC)率分别为68.9和55.7%。 3年和5年总生存率分别为88.6%和81.1%。放射剂量≤13 vs> 13 Gy治疗的肿瘤的LC呈恶化趋势。在我们的系列中没有发现放射性坏死或第二恶性肿瘤。 >结论本报告是最大的针对2级脑膜瘤的GKRS系列研究之一,表明GKRS是对2级脑膜瘤患者的安全有效治疗方式,具有持久的肿瘤控制和最小的毒性。对于2级脑膜瘤患者,GKRS辅助治疗可被视为合理的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号